Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTRIVA: Vedolizumab + Upadacitinib in Crohn's Disease
NCT06227910Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 26
01
Overview
A Phase 3 trial of vedolizumab, upadacitinib in Crohn's disease, sponsored by Takeda. Started Jan 2025; status: recruiting.
02
Drugs
vedolizumabupadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06227910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06227910.